Products for Research Use Only
RegisterLogin

Vobramitamab

CAT: 0804-HY-P99101-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99101-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma[1][2][3][4].
CAS Number
2490556-50-6
Product Name Alternative
AEX-4089; MGC026 antibody
UNSPSC
12352203
Target
ADC Antibody
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vobramitamab.html
Purity
99.67
Solubility
10 mM in DMSO|H2O
Smiles
[Vobramitamab]
Molecular Weight
(144.691 kDa)
References & Citations
[1]Brignole C, et al. Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models[J]. Cancer Research, 2023, 83 (7_Supplement) : 2981-2981.|[2]Brignole C, et al. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. J Immunother Cancer. 2023 Sep;11 (9) :e007174.|[3]Danielle C Kirkey MD, et al. CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate. Blood.Volume 142, Supplement 1, 2 November 2023, Page 5958|[4]Scribner JA, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Mol Cancer Ther. 2020 Nov;19 (11) :2235-2244.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2

Alternative Products

CatalogName
abx831771-01Vobramitamab
GTR18398563-01Vobramitamab Antibody
CBA1082-01Vobramitamab Biosimilar
E55B0871Vobramitamab (Reference antibody)
HV612066-01Research Grade Vobramitamab
A138620Vobramitamab Biosimilar (Monoclonal, IgG1)
ICH5985-50mgVobramitamab Biosimilar - Research Grade
GTR18780887-01(Vobramitamab) Biosimilar Reference Antibody
GTR18697243-01Vobramitamab Human Monoclonal Antibody
048309B7-H3/CD276 (Vobramitamab) discontinued

Popular Products